Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial

Journal:

Nature Communications

Published:

2025-07-01

DOI:

10.1038/s41467-025-61213-2

Affiliations:

12

Authors:

30

Go to article

Institutions	Authors	Share
Shengjing Hospital of China Medical University, China	18.000000 18.000000	0.60
The First Hospital of China Medical University, China	2.000000	0.07
Liaoning Cancer Hospital and Institute, China	2.000000	0.07
Anshan Cancer Hospital, China	1.000000	0.03
Yan'an People's Hospital, China	1.000000	0.03
Panjin Liaohe Oilfield Gem Flower Hospital, China	1.000000	0.03
Benxi Central Hospital, China	1.000000	0.03
First Affiliated Hospital of Jinzhou Medical University, China	1.000000	0.03
Harbin Medical University Cancer Hospital, China	1.000000	0.03
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA)	1.000000	0.03
Hengrui, China	1.000000	0.03

Interested in Oncology and Carcinogenesis?